Clostridium Difficile Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Clostridium Difficle Tests Market Report Overview
The clostridium difficle tests market size was valued at $172.1 million in 2023. Clostridium difficile tests are carried out to diagnose the bacterium, commonly known as C. diff, which is a major cause of serious diarrheal infections and may also cause colon cancer.
Clostridium Difficle Tests Market Outlook 2023-2033 ($ Million)
Buy the Full Report for More Insights on the Clostridium Difficle Tests Market Forecast, Download a Free Sample Report
The clostridium difficle tests market research report explains the market behavior, which will help identify quantitative market trends within the in vitro diagnostics therapeutic area. The report has extensively covered pipeline products and technologies, which will help in identifying companies with the most robust pipeline. This, in turn, will assist in predictive analysis for designing in-licensing and out-licensing strategies. The clostridium difficle tests market model also discusses the detailed impact of COVID-19 on the clostridium difficle tests market for 2020 and beyond.
Market Size (2023) | $172.1 million |
Historic Period | 2015-2023 |
Forecast Period | 2023-2033 |
Key Segments |
|
Key Regions |
|
Key Companies |
|
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Clostridium Difficle Tests Market Dynamics
The clostridium difficile tests market is expected to increase during the forecast period, largely due to increases in overall population size and thus the number of suspected infection cases. The market is dominated by markets in North America and Europe, with fewer sales occurring in other regions. Diminished sales in the APAC, South America, and Middle East & Africa, continue to be negatively impacted by under-reporting of the disease and the lack of uniform testing algorithms.
Buy the Full Report for Additional Clostridium Difficle Tests Market Dynamics, Download a Free Sample Report
Clostridium Difficle Tests Market Segments
The key segments in the clostridium difficle tests market are Clostridium difficile Culture Tests, Clostridium difficile Nucleic Acid Amplification Tests (NAATs), Clostridium difficile Toxin Enzyme Immuno Assay/Enzyme-Linked Immunosorbent Assay (EIA/ELISA) Tests, Dual Toxin and Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests, and Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests.
In 2023, the Clostridium difficile Nucleic Acid Amplification Tests (NAATs) was the leading market segment. Primary participants indicate that in most countries, NAATs tend to be used as confirmatory tests, likely due to their high sensitivity and costlier price. In the US, adoption of NAATs is much higher, with some US institutions using a single NAAT to diagnose C. difficile infection, rather than a multi-step testing algorithm.
Clostridium Difficle Tests Market Analysis by Segments, 2023 (%)
Buy the Full Report for More Segment-Wise Insights about the Clostridium Difficle Tests Market Segments, Download a Free Sample Report
Clostridium Difficle Tests Market Segmentation by Regions
The key regions in the clostridium difficle tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2023, North America emerged as the leading contributor to the regional market.
The North American market for Clostridium difficile tests is expected to grow throughout the forecast period, largely due to increases in overall population size and thus the number of suspected infection cases. The US Clostridium difficile tests IVD market is large compared to many other countries, due to strong sales of NAAT devices. Primary participants and secondary sources indicate that in many US institutions, NAAT is used as the initial method for diagnosing CDI. Conversely, in Canada and Mexico, the devices used for initial testing of suspected CDI cases tend to be toxin EIA tests and GDH EIA tests, respectively.
Clostridium Difficle tests Market Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights in the Clostridium Difficle Tests Market, Download A Free Sample Report
Clostridium Difficle Tests Market – Competitive Landscape
The key companies in the clostridium difficle tests market are Leica Microsystems Inc. + Cepheid Inc., TECHLAB Inc., Meridian Bioscience Inc, bioMerieux SA, and Thermo Fisher Scientific Inc among others. In 2023, Leica Microsystems Inc + Cepheid Inc accounted for the highest clostridium difficle tests market share and value.
Clostridium Difficle Tests Market Analysis by Companies, 2023 (%)
Buy the Full Report for More Company-Wise Insights into the Clostridium Difficle Tests Market, Download a Free Sample Report
Segments Covered in this Report
Clostridium Difficle Tests Segment Outlook ($ Million, 2015-2033)
- Clostridium difficile Culture Tests
- Clostridium difficile Nucleic Acid Amplification Tests (NAATs)
- Clostridium difficile Toxin Enzyme Immuno Assay/Enzyme-Linked Immunosorbent Assay (EIA/ELISA) Tests
- Dual Toxin and Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests
- Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests
Clostridium difficle tests Regional Outlook ($ Million, 2015-2033)
- Asia-Pacific
- Europe
- Middle East and Africa
- North America
- South and Central America
Key Inclusions of the market model are –
Currently marketed Clostridium difficle tests market and evolving competitive landscape –
- Insightful review of the key industry trends.
- Annualized total Clostridium difficle tests market revenue by segment and market outlooks from 2015-2033.
- Market-level data on units, average selling prices, and market values.
Global, Regional, and Country level market specific insights –
- Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the Clostridium difficle tests market.
- Competitive dynamics insights and trends provided for the Clostridium difficle tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Danaher Corp, TechLab, Inc., Meridian Bioscience Inc., bioMerieux SA, Thermo Fisher Scientific Inc., LG Chem Ltd, Microbiologics Inc., American Type Culture Collection, DiaSorin SpA, and others.
Countries covered – United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Scope
This market model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for
- CMO executives who must have a deep understanding of the clostridium difficle tests marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives must understand crucial components of the supply base to make decisions about supplier selection and management.
- Private equity investors who need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to –
- Understand the impact of COVID-19 on clostridium difficle tests.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving clostridium difficle tests.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the clostridium difficle tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific clostridium difficle tests market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
TechLab, Inc.
Meridian Bioscience Inc
bioMerieux SA
Thermo Fisher Scientific Inc
LG Chem Ltd
Microbiologics Inc
American Type Culture Collection
DiaSorin SpA
Frequently asked questions
-
What was the clostridium difficle tests market size in 2023?
The clostridium difficle tests market size was $172.1 million in 2023.
-
Which was the leading segment in the clostridium difficle tests market in 2023?
In 2023, the clostridium difficile Nucleic Acid Amplification Tests (NAATs) was the leading market segment.
-
Which region held the largest share of the clostridium difficle tests market in 2023?
North America was the largest regional market for clostridium difficle tests in 2023.
-
Which are the leading players in the clostridium difficle tests market?
The key companies in the clostridium difficle tests market are Danaher Corp, TechLab, Inc., Meridian Bioscience Inc., bioMerieux SA, Thermo Fisher Scientific Inc., LG Chem Ltd, Microbiologics Inc., American Type Culture Collection, DiaSorin SpA, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.